[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.
28 Nov, 2021 | 21:30h | UTCCommentary: New data, analyses take some of the shine off Merck’s Covid pill – STAT
Related:
8 lingering questions about the new Covid pills from Merck and Pfizer.
The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.
Merck to allow other nations to produce new COVID-19 antiviral.
Video: Merck’s Covid pill could transform treatment. Here’s how it works.
How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.
What we know — and don’t know — about Merck’s new Covid-19 pill.
Merck’s Covid-19 pill is great news but may not be a game-changer.
Video | A Pill For COVID? A Doctor Explains Molnupiravir.
Commentaries on Twitter
Disappointing!!
?Merck Provides Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19
N=1433
RRR fell from 50% to 30%
Absolute Risk reduction only 3% #IDTwitter https://t.co/aX2b3xrdnB pic.twitter.com/uXUSQRNWC7— Antibiotic Stewa®️x? Bassam Ghanem (@ABsteward) November 26, 2021
Disappointing from Merck. Updated data for efficacy of their Molnupiravir pill in full trial drops down to 30% from 50%, absolute reduction to 3 from 7 per 100 at interim analysis https://t.co/PyfIBnFNC7 pic.twitter.com/SBDL92aG5M
— Eric Topol (@EricTopol) November 26, 2021